Name | Title | Contact Details |
---|---|---|
Robert Weiskopf |
Chief Financial Officer | Profile |
Martin Redmon |
Chief R&D Officer | Profile |
Mike Malynn |
Vice President of Human Resources | Profile |
Katy Strei |
Chief People Officer | Profile |
Reenie McCarthy |
Chief Executive Officer | Profile |
Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
Xcellerex is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Probiotics for Plants, We design microbes for more sustainable agriculture.
Genome Atlantic is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.